RxDoctor Payments DataLook up a doctor →

Sandeep Bansal, MD

Pulmonary Disease · du Bois, PANPI 1215105267

Payments from drug & device makers

$8,874,086in general payments, 2019–2025

Across 2,606 payments — averaging $3405.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$2.8M
  • AstraZeneca$2.2M
  • GSK$1.1M
  • Sanofi US Services Inc.$855K
  • Boehringer Ingelheim$449K
  • Sanofi$287K
  • plus $1.2M from 54 others
$1,380in research payments, 2019–2025

Across 7 payments — averaging $197.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$1K

What the payments were for

  • Consulting fees$147,94610%
  • Speaking & faculty fees$1,059,06374%
  • Travel & lodging$181,70613%
  • Food & beverage$37,1133%
  • Education$4230%
  • Entertainment$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.146$2,759,658
AstraZeneca(2 entities)224$2,189,209
GSK748$1,106,852
Sanofi US Services Inc.144$854,966
Boehringer Ingelheim122$449,262
Sanofi178$286,872
Regeneron Healthcare Solutions, Inc.244$269,439
Johnson & Johnson(2 entities)60$199,290
Amgen17$93,132
Pulmonx Corporation31$92,414
Regeneron34$82,013
Shionogi Inc9$80,520
Verona Pharma, Inc.31$57,677
Insmed, Inc.104$48,372
Takeda Pharmaceuticals U.S.A., Inc.61$44,953
Concordia Laboratories Inc.6$34,201
Astrazeneca UK Limited9$30,707
Veran Medical Technologies, Inc.20$28,535
Boehringer Ingelheim International GmbH122$27,923
Boston Scientific3$21,260
Mylan Specialty L.p.30$18,349
Noah Medical Corporation16$14,451
Pfizer7$13,937
Chiesi USA, Inc.4$12,212
Abbott4$10,657
Viatris Specialty LLC6$8,328
Ethicon Endo-surgery Inc.4$7,353
Pinnacle Biologics, Inc23$7,319
Covidien LP2$6,255
Medical Device Business Services, Inc.2$4,400
Viiv Healthcare Company3$3,649
Genentech USA, Inc.7$1,895
Inspire Medical Systems, Inc.4$1,829
United Therapeutics Corporation7$1,448
Actelion Pharmaceuticals US, Inc.33$966
Novartis22$529
Philips North America LLC23$437
Galvanize Therapeutics, Inc1$400
Intuitive Surgical7$381
Biosense Webster, Inc.3$281
Electromed, Inc.11$204
Baxter Healthcare6$175
Novo Nordisk3$164
Lilly USA, LLC4$163
Rocket Medical LLC1$136
Merit Medical Systems Inc1$120
Merck5$104
Grifols USA, LLC5$89
Vifor Pharma, Inc.3$80
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)24$72
Ambu Inc.2$66
Medtronic1$57
Paratek Pharmaceuticals, Inc.4$49
Mauna Kea Technologies, Inc.1$46
Nabriva Therapeutics, PLC2$28
Olympus Corporation Of The Americas1$26
Gilead2$24
Sunovion Pharmaceuticals Inc.1$23
Shire North American Group Inc1$23
Avadel CNS Pharmaceuticals, LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,874,086 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$152,997
Medicare patients
535
Services billed
2,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab151$606,785
Trelegy ElliptaFluticasone/Umeclidin/Vilanter704$536,982
GlassiaAlpha-1-Proteinase Inhibitor26$368,275
OfevNintedanib Esylate29$357,258
NucalaMepolizumab49$183,757
Prolastin CAlpha-1-Proteinase Inhibitor11$154,985
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr220$118,163
TezspireTezepelumab-Ekko25$111,626
Breztri AerosphereBudesonide/Glycopyr/Formoterol119$82,487
Breo ElliptaFluticasone/Vilanterol170$71,922
Spiriva RespimatTiotropium Bromide97$49,318
Pirfenidone12$44,548
Fluticasone-SalmeterolFluticasone Propion/Salmeterol212$33,264
Stiolto RespimatTiotropium Br/Olodaterol Hcl47$26,782
Arnuity ElliptaFluticasone Furoate109$23,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$1,106,852$947,4671,285 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$449,262$433,357173 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$44,953$368,27526 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$2,189,209$197,804161 claims
Grifols USA, LLCProlastin C$89$154,98511 claims
MerckAsmanex$104$2,02817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →